← Back

Shanghai Shen Lian Biomedical Corp

Shanghai Shen Lian Biomedical Corp is a Chinese company engaged in the research, development, production, and sale of veterinary biological products. Its offerings include swine vaccines, ruminant vaccines, diagnostic reagents, and pet biological products. The company also provides monoclonal antibody drugs for HIV treatment, anti-allergy anti-IgE, and anti-herpes simplex virus, as well as foot-and-mouth disease vaccines for pigs, cattle, and sheep, and porcine circovirus type 2 subunit vaccines. Founded in 2001, it is headquartered in Shanghai, China.

Country
Price · split & dividend adjusted
News & notes moving 688098.CG
688098.CG▼

Shenlian Biotech's 2026 Interim Report Shows Net Loss Widening to 19.1464 Million Yuan

Shenlian Biotech released its 2026 interim report, showing total operating revenue of 112 million yuan, down 8.05 percent year on year. Net profit attributable to the parent company was a loss of 19.1464 million yuan, with the loss widening by 6.2767 million yuan compared with the same period last year. Net cash flow from operating activities was negative 64.6641 million yuan, a year-on-year decrease of 25.2751 million yuan. The company's asset-liability ratio was 9.85 percent, gross margin was 57.36 percent, return on equity was negative 1.38 percent, and diluted earnings per share was negative 0.05 yuan. The number of shareholders was 9,297, and the top ten shareholders held 55.79 percent of the total share capital.
688098.CG ▼
Jiemian·19dRead more →
688098.CG▲

Shenlian Bio Receives Approval Number for Bivalent Synthetic Peptide Vaccine Against Swine Foot-and-Mouth Disease

Shenlian Bio's Lanzhou branch has been approved to produce a bivalent synthetic peptide vaccine against swine foot-and-mouth disease types O and South Africa 1, and has obtained a temporary veterinary drug product approval number. The product uses a synthetic polypeptide technology platform and complements the company's two previously approved inactivated vaccines containing the South Africa 1 strain, forming a product matrix of South Africa 1 foot-and-mouth disease vaccines covering pigs, cattle, and sheep. Before the product can be marketed and sold, procedures such as batch release still need to be completed. Specific sales will be affected by factors such as epidemic prevention policies and market capacity, and returns are uncertain.
688098.CG ▲
CLS·25dRead more →
688098.CG▲3

Shenlian Bio's Live Swine Pseudorabies Vaccine (JS-A1 Strain) Receives Veterinary Drug Approval Number

Shenlian Bio announced that the live swine pseudorabies vaccine (JS-A1 strain) produced by its Lanzhou branch has obtained the veterinary drug product approval number document issued by the Ministry of Agriculture and Rural Affairs. The approval was granted after review in accordance with regulations such as the Veterinary Drug Management Regulations and the Administrative Measures for Veterinary Drug Product Approval Numbers, permitting production.
688098.CG ▲
CLS·60dRead more →
© 2026 MarketDXAsset